For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
HCA Healthcare Inc (NYSE: HCA) closed the day trading at $419.08 up 1.01% from the previous closing price of $414.89. In other words, the price has increased by $1.01 from its previous closing price. On the day, 1.18 million shares were traded. HCA stock price reached its highest trading level at $422.43 during the session, while it also had its lowest trading level at $414.06.
Ratios:
For a better understanding of HCA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 94.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.45. For the most recent quarter (mrq), Quick Ratio is recorded 0.86 and its Current Ratio is at 0.98.
On July 16, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $394.
Wells Fargo Upgraded its Underweight to Equal Weight on May 29, 2025, while the target price for the stock was maintained at $385.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 08 ’25 when Cuffe Michael S. bought 3,836 shares for $418.84 per share.
Cuffe Michael S. sold 3,836 shares of HCA for $1,606,670 on Sep 08 ’25. The EVP and Chief Clinical Officer now owns 31,503 shares after completing the transaction at $418.84 per share. On May 13 ’25, another insider, Foster Jon M, who serves as the EVP and COO of the company, sold 15,698 shares for $369.32 each. As a result, the insider received 5,797,661 and left with 12,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCA now has a Market Capitalization of 98061991936 and an Enterprise Value of 146542002176. As of this moment, HCA’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.60, and their Forward P/E ratio for the next fiscal year is 14.76. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.35. Its current Enterprise Value per Revenue stands at 2.016 whereas that against EBITDA is 10.107.
Stock Price History:
The Beta on a monthly basis for HCA is 1.41, which has changed by 0.031124711 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, HCA has reached a high of $420.98, while it has fallen to a 52-week low of $289.98. The 50-Day Moving Average of the stock is 7.75%, while the 200-Day Moving Average is calculated to be 18.88%.
Shares Statistics:
Over the past 3-months, HCA traded about 1.35M shares per day on average, while over the past 10 days, HCA traded about 1375660 shares per day. A total of 236.14M shares are outstanding, with a floating share count of 166.32M. Insiders hold about 28.92% of the company’s shares, while institutions hold 64.12% stake in the company. Shares short for HCA as of 1757894400 were 4228281 with a Short Ratio of 3.13, compared to 1755216000 on 4123693. Therefore, it implies a Short% of Shares Outstanding of 4228281 and a Short% of Float of 2.5899999.
Dividends & Splits
HCA’s forward annual dividend rate is 2.82, up from 2.76 a year ago. Against a Trailing Annual Dividend Yield of 0.0066523654. The stock’s 5-year Average Dividend Yield is 0.75.
Earnings Estimates
The stock of HCA Healthcare Inc (HCA) is currently being evaluated by 18.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $7.34, with high estimates of $7.75 and low estimates of $6.4.
Analysts are recommending an EPS of between $26.89 and $25.63 for the fiscal current year, implying an average EPS of $26.35. EPS for the following year is $28.42, with 23.0 analysts recommending between $29.54 and $26.35.
Revenue Estimates
19 analysts predict $18.55B in revenue for . The current quarter. It ranges from a high estimate of $18.85B to a low estimate of $18.36B. As of . The current estimate, HCA Healthcare Inc’s year-ago sales were $17.49BFor the next quarter, 19 analysts are estimating revenue of $19.5B. There is a high estimate of $20.1B for the next quarter, whereas the lowest estimate is $19.2B.
A total of 23 analysts have provided revenue estimates for HCA’s current fiscal year. The highest revenue estimate was $75.77B, while the lowest revenue estimate was $74.48B, resulting in an average revenue estimate of $75B. In the same quarter a year ago, actual revenue was $70.6BBased on 22 analysts’ estimates, the company’s revenue will be $78.42B in the next fiscal year. The high estimate is $80.6B and the low estimate is $76.41B.
